Oxford BioMedica plc (“Oxford BioMedica”, “the Company” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, announced on 4 May 2018 a proposed share capital Consolidation of the existing ordinary share capital of the Company. The effect of the proposed Consolidation will be to reduce the number of issued ordinary shares in the Company by a factor of 50 whilst increasing the trading price of each Existing Ordinary Share.
The Board considers the Consolidation to be in the best interests of the Company and its Shareholders. It believes that the effect of the Consolidation will be to improve market liquidity by reducing the volatility and spread of trading activity in the Company’s New Consolidated Ordinary Shares and make trading in the Company’s shares more attractive to a broader range of institutional investors and other members of the investing public, both overseas and in the UK.
As it is proposed that all existing ordinary shareholdings in the Company be consolidated, the proportion of the issued ordinary share capital of the Company held by each Shareholder immediately before and after the Consolidation will remain relatively unchanged, other than for small changes that may arise from the rounding for fractional entitlements.
A Circular, which provides details of the Consolidation and includes a Notice of General Meeting has been sent to shareholders and a copy can be obtained from our website.
If you are in any doubt with regard to your current shareholding in Existing Ordinary Shares or the Consolidation, you should contact our registrar, Link Asset Services, on: +44 (0) 371 664 0321 between
9.00 a.m. and 5.30 p.m. on any Business Day.
